Related Experiment Video
Updated: Jun 20, 2026
04:41
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
What has changed with riluzole?
V Meininger1, L Lacomblez, F Salachas
1Fédération de Neurologie Mazarin, Division Mazarin, Hôpital de la Salpêtrière, Paris, France. vincent.meininger@psl.ap-hop-paris.fr
Journal of Neurology
|August 29, 2009
Summary
Riluzole remains the first standard treatment for amyotrophic lateral sclerosis (ALS), offering hope by slowing disease progression and impacting survival rates. Further research explores its mechanisms and optimal administration for ALS patients.
Area of Science:
- Neuroscience and Pharmacology
- Amyotrophic Lateral Sclerosis (ALS) Research
Background:
- Riluzole was the first standard treatment introduced for amyotrophic lateral sclerosis (ALS) in the early 1990s.
- Its introduction spurred research into the role of glutamate in ALS pathogenesis.
- Subsequent research has revealed complexities in riluzole's mechanisms and identified other potential ALS disease pathways, including oxidative stress and growth factors.
Purpose of the Study:
- To review the impact and changes in the field of ALS treatment and research five years after riluzole's introduction.
- To evaluate the clinical efficacy and patient-reported outcomes of riluzole.
- To assess the broader impact of riluzole on ALS research collaborations and patient care.
Main Methods:
- Review and analysis of clinical trial data and historical databases comparing riluzole's effects.
- Evaluation of published studies on riluzole's impact on survival rates and muscle strength decline.
- Assessment of riluzole's influence on patient hope and caregiver collaborations.
Main Results:
- Riluzole's impact on survival rates is supported by historical data, though debated.
- Evidence suggests riluzole may positively influence the decline in muscle strength.
- Riluzole has provided significant psychological hope for ALS patients, shifting the paradigm from 'no hope' to managing disease progression.
Conclusions:
- Riluzole continues to be a valuable standard treatment for ALS, offering tangible benefits in slowing disease progression and potentially preserving muscle strength.
- Further research is needed to optimize riluzole administration based on individual patient clinical status.
- Riluzole has fostered crucial national and international collaborations, advancing therapeutic trials and standards of care for ALS.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
01:27Restless Leg Syndrome and Night Terrors
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...